Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2015

View Archived Issues

BMS initiates phase I trial of BMS-986171

Blood level of UCH-L1 is a biomarker of traumatic brain injury

Researchers at CSIC present alpha-synuclein overexpressing mouse model

miRagen Therapeutics begins first clinical trial for antifibrosis candidate MRG-201

Protein Sciences receives U.S. Department of Defense grant to develop adenovirus vaccine

Enterome Bioscience and Gustave Roussy establish microbiome collaboration in immune-oncology

Daratumumab granted U.S. orphan status for diffuse large B-cell lymphoma

The FDA grants orphan drug designation to Bone Therapeutics' bone marrow derived cells

Early clinical data for Macrogenics' MGA-271

Daiichi Sankyo presents preclinical and phase I results for DS-3032b

Amplyx Pharmaceuticals secures funding to advance APX-001

FDA approves Tagrisso to treat certain patients with NSCLC

SOM Biotech and Vall d'Hebron complete trial in patients with TTR amyloidosis

Genfit reveals design of phase III trial of elafibranor for NASH

Finnish clearance for first-in-human study of Lymfactin for breast cancer-associated lymphedema

Auven releases promising findings from pivotal study of Seciera for dry eye disease

Two Baxalta hemophilia A products approved in Europe, U.S.

Preclinical data on TBI-302 that led to advancement into phase I for HCC

Abeta42-targeting MAb MEDI-1814 well tolerated in patients with Alzheimer's disease

Piramal Enterprises reports cannabinoid CB1 receptor antagonists

Isis Pharmaceuticals describes gapped oligonucleotides

Mitsubishi Tanabe Pharma presents ENPP2 inhibitors

Merck & Co. and Mochida Pharmaceutical divulge FIXa inhibitors

NIP-565: a JAK-1 inhibitor for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...